Aranda S et al. Meeting the support and information needs of women with advanced breast cancer: A randomised controlled trial. Br J Cancer 2006;95(6):667-73. Abstract
Browall M et al. Postmenopausal women with breast cancer: Their experiences of the chemotherapy treatment period. Cancer Nurs 2006;29(1):34-42. Abstract
Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005;353(16):1652-4. Abstract
Carlson RW et al; National Comprehensive Cancer Network. NCCN task force report: Adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006;4(Suppl 1):1-26. Abstract
Duric VM et al. Patients’ preferences for adjuvant endocrine therapy in early breast cancer: What makes it worthwhile? Br J Cancer 2005;93(12):1319-23. Abstract
Fallowfield L et al. Patients' preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Ann Oncol2006;17(2):205-10. Abstract
Forrest G et al. Breast cancer in the family — Children's perceptions of their mother's cancer and its initial treatment: Qualitative study. BMJ 2006;332(7548):998-1003. Abstract
Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract
Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53. Abstract
Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract
Gray RE et al. Supportive care provided by physicians and nurses to women with breast cancer. Results from a population-based survey. Support Care Cancer 2002;10(8):647-52. Abstract
HERA Study Team. Trastuzumab (H: Herceptin®) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: The HERA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 11.
Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353(16):1734-6. Abstract
Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104(2):236-9. Abstract
Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract
Jakesz R et al; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract
Jonat W et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone responsive early breast cancer: A meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 18.
Lengacher CA et al. Relief of symptoms, side effects, and psychological distress through use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 2006;33(1):97-104. Abstract
Lynn J. The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer — Focus on fulvestrant. Cancer Nurs 2002;25(Suppl 2):12-7. Abstract
Mamounas E et al. Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20.Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 29.
McGurk R et al. Information provision for patients by breast cancer teams about the side-effects of hormone treatments. Eur J Cancer 2006;42(12):1760-7. Abstract
McKenney SA. The role of the nurse practitioner in the care of young women with breast cancer. Breast Dis 2005-2006;23:115-21. Abstract
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial conducted by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004a;351(27):2817-26. Abstract
Paik S et al. Expression of the 21 genes in the recurrence score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Presentation. San Antonio Breast Cancer Symposium 2004b;Abstract 24.
Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005;Abstract 556.
O’Shaughnessy J et al. ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: A phase III trial. Presentation. San Antonio Breast Cancer Symposium 2003;Abstract 44.
Owers R. Clinical experience with fulvestrant ('Faslodex'): A nurse's perspective. Eur J Oncol Nurs 2004;8(Suppl 2):89-94. Abstract
Robert N et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 2073.
Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract
Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005. No abstract available
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Slamon D et al, on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC®T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2005;Abstract 1.
Sura W et al. Level of fatigue in women receiving dose-dense versus standard chemotherapy for breast cancer: A pilot study. Oncol Nurs Forum 2006;33(5):1015-21. Abstract
Vogel WH. The advanced practice nursing role in a high-risk breast cancer clinic. Oncol Nurs Forum 2003;30(1):115-22. Abstract
Ziegler J, Citron M. Dose-dense adjuvant chemotherapy for breast cancer. Cancer Nurs 2006;29(4):266-72. Abstract
